araag2/HINT huggingface dataset:
Clinical trial NCT02224703 (phase 3, status: completed)
Conditions: epilepsy, dravet syndrome
ICD codes: G40.803, G40.804, G40.911, G40.919, G40.B11, G40.B19, G40.801, G40.833, G40.834
Drugs: gwp42003-p, placebo control
SMILES: CCCCCC1=CC(O)=C([C@@H]2C=C(C)CC[C@H]2C(C)=C)C(O)=C1, CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1
Eligibility criteria:

        Key Inclusion Criteria:

          -  Participant must have been male or female, aged between 2 and 18 years (inclusive).

          -  Participant must have had a documented history of Dravet syndrome that was not
             completely controlled by current antiepileptic drugs.

          -  Participant must have been taking 1 or more antiepileptic drugs at a dose that had
             been stable for at least 4 weeks.

          -  All medications or interventions for epilepsy (including ketogenic diet and vagus
             nerve stimulation) must have been stable for 4 weeks prior to screening and
             participant was willing to maintain a stable regimen throughout the study.

        Key Exclusion Criteria:

          -  Participant had clinically significant unstable medical conditions other than
             epilepsy.

          -  Participant had clinically relevant symptoms or a clinically significant illness in
             the 4 weeks prior to screening or randomization, other than epilepsy.

          -  Participant was currently using or had in the past used recreational cannabis,
             medicinal cannabis, or synthetic cannabinoid-based medications (including Sativex®)
             within the 3 months prior to study entry and was unwilling to abstain for the duration
             for the study.

          -  Participant had any known or suspected hypersensitivity to cannabinoids or any of the
             excipients of the investigational medicinal products.

          -  There were plans for the participant to travel outside their country of residence
             during the study.

          -  Any history of suicidal behavior or any suicidal ideation of type four or five on the
             Columbia-Suicide Severity Rating Scale (Children's) at screening.
Clinical trial NCT02227862 (phase 3, status: completed)
Conditions: type 1 diabetes
ICD codes: E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: mylan's insulin glargine, lantus®
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with an established diagnosis of T1DM per ADA 2014 criteria

          -  Body mass index (BMI) of 18.5 to 35 kg/m2 at screening (both values inclusive).

          -  Glycosylated hemoglobin (HbA1c) ≤9.5% at screening.

          -  Hemoglobin ≥9.0 g/dL at screening.

        Exclusion Criteria:

          -  History of hypersensitivity to any of the active or inactive ingredients of the
             insulin/insulin analogue preparations used in the trial, OR history of significant
             allergic drug reactions.

          -  History of use of animal insulin within the last 3 years or use of biosimilar insulin
             glargine at any time prior.

          -  History of use of a regular immunomodulator therapy in the 1 year prior to screening.

          -  History of ≥2 episodes of severe hypoglycemia within the 6 months before screening or
             history of hypoglycemia unawareness (a sample questionnaire is provided in Appendix
             I), as judged by the investigator.

          -  History of ≥1 episodes of diabetic ketoacidosis or emergency room visits for
             uncontrolled diabetes leading to hospitalization within the 6 months prior to
             screening.

          -  Serological evidence of human immunodeficiency virus (HIV), hepatitis B (HbSAg) or
             hepatitis C (HCVAb) antibodies at screening.

          -  History of drug or alcohol dependence or abuse during the 1 year prior to screening.
Clinical trial NCT02227875 (phase 3, status: completed)
Conditions: type 2 diabetes
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: mylan's insulin glargine, lantus®
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with an established diagnosis of T2DM per ADA 2014 criteria who also fulfill
             the following:

               -  Diagnosis established 1 year prior to screening

               -  Insulin-naïve OR

               -  On Lantus® once daily at stable dose (±15% variation in dose) for at least 3
                  months prior to screening

          -  Body mass index (BMI) of 18.50 to 40.00 kg/m2 at screening (both values inclusive).

          -  Stable weight, with no more than 5 kg gain or loss, in the 3 months prior to
             screening; this information will be collected by patient interview during medical
             history.

          -  Hemoglobin ≥9.0 g/dL at screening

          -  Glycosylated hemoglobin (HbA1c) of <10.5% or between 7.5 to 10.5% for insulin naïve
             patients at screening.

        Exclusion Criteria:

          -  History of hypersensitivity to any of the active or inactive ingredients of the
             insulin/insulin analog preparations used in the trial, OR history of significant
             allergic drug reactions.

          -  History of use of animal insulin within the last 3 years, any insulin other than
             Lantus® within the last 3 months prior to screening, or use of biosimilar insulin
             glargine at any time prior to screening.

          -  Patients requiring basal-bolus insulin therapy or who in the opinion of the
             investigator require mealtime insulin in order to achieve glycemic control.

          -  Regular use of immune-modulator therapy in the 1 year prior to screening.

          -  History of ≥2 episodes of severe hypoglycemia within the 6 months before screening or
             history of hypoglycemia unawareness (a sample questionnaire is provided in Appendix I)
             as judged by the investigator.

          -  History of ≥1 episode of hyperglycemic hyperosmolar coma or emergency room visits for
             uncontrolled diabetes leading to hospitalization within the 6 months prior to
             screening.

          -  Serological evidence of human immunodeficiency virus (HIV), hepatitis B (HbSAg) or
             hepatitis C (HCVAb) antibodies at screening.

          -  History of drug or alcohol dependence or abuse during the 1 year prior to screening.

          -  Receipt of another investigational drug in the 3 months prior to screening (or as per
             local regulations), or if the screening visit is within 5 half-lives of another
             investigational drug (whichever is longer), or scheduled to receive another
             investigational drug during the current trial period.
Clinical trial NCT02229383 (phase 3, status: completed)
Conditions: diabetes mellitus
ICD codes: P70.2, O24.92, Z83.3, E10.65, E10.9, E11.65, E11.9
Drugs: exenatide, exenatide matching placebo
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Inclusion criteria:

          -  Has a diagnosis of Type 2 Diabetes Mellitus (T2DM)

          -  Has HbA1c of 7.5% to 12.0%, inclusive, at Visit 1 (Screening).

          -  Has fasting plasma glucose (FPG) concentration <280 mg/dL (15.6 mmol/L) at Visit 1
             (Screening)

          -  Treated with basal insulin glargine at a dose of ≥20 units/day once daily for at least
             6 weeks prior to Screening, in combination with diet and exercise alone or in
             combination with:

               1. a stable dose of metformin (≥1500 mg/day) for at least 8 weeks prior to Visit 1

               2. a stable dose of metformin (≥1500 mg/day) for at least 8 weeks prior to Visit 1
                  (Screening) and a stable dose of sulfonylurea for at least 8 weeks prior to the
                  Screening visit

        Exclusion criteria:

          -  Serum calcitonin concentration ≥40 pg/mL (≥40 ng/L) at Visit 1 (Screening)

          -  History of, or currently have, acute or chronic pancreatitis, or have triglyceride
             concentrations ≥500 mg/dL (≥5.65 mmol/L) at Visit 1

          -  Positive serological test for hepatitis B or hepatitis C
Clinical trial NCT02229396 (phase 3, status: completed)
Conditions: diabetes mellitus
ICD codes: P70.2, O24.92, Z83.3, E10.65, E10.9, E11.65, E11.9
Drugs: exantide with dapagliflozin, exentide, dapagliflozin
SMILES: CN(C)C(=N)NC(N)=N, CN(C)C(=N)NC(N)=N
Eligibility criteria:

        Inclusion criteria

          -  Has a diagnosis of T2DM.

          -  Has HbA1c of 8.0% to 12.0%, inclusive, at Visit 1 and Visit 2.

          -  Treated with a stable dose of metformin ≥1500 mg/day for at least 2 months prior to
             Screening.

        Exclusion criteria

          -  FPG ≥280 mg/dL (15.6 mmol/L).

          -  Serum calcitonin concentration ≥40 pg/mL (≥40 ng/L) at Visit 1 (Screening)

          -  Clinically significant abnormal free T4 values or patients needing initiation or
             adjustment of thyroid treatment according to the investigator.

          -  Abnormal thyroid stimulating hormone (TSH) value at Screening will be further
             evaluated by free T4.Patients with clinically significant abnormal free T4 values will
             be excluded.

          -  Known active proliferative retinopathy.

          -  History of, or currently have, acute or chronic pancreatitis, or have triglyceride
             concentrations ≥500 mg/dL (≥5.65 mmol/L) at Visit 1

          -  History or presence of inflammatory bowel disease or other severe GI diseases,
             particularly those which may impact gastric emptying, such as gastroparesis or pyloric
             stenosis.

          -  History of gastric bypass surgery or gastric banding surgery, or either procedure is
             planned during the time period of the study. Current use of gastric balloons is also
             excluded.
Clinical trial NCT02231086 (phase 3, status: active, not recruiting)
Conditions: colorectal neoplasms, peritoneal neoplasms
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, K65.1, K66.0, N99.4, N73.6, R88.0, Z49.32, Z49.02
Drugs: standard adjuvant systemic chemotherapy
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  age between 18 and 75 years

          -  Intention to start routine adjuvant systemic therapy

          -  adequate clinical condition to undergo simultaneous HIPEC or re- laparoscopy or
             re-laparotomy with HIPEC within either 10 days or between week 5-8 from --primary
             resection

          -  written informed consent

          -  white blood cell count of at least 3000/mm3, platelet count of at least 100.000/mm3

          -  no bleeding diathesis or coagulopathy

          -  normal creatinine or creatinine clearance of at least 50 ml/min

        Exclusion Criteria:

          -  postoperative complications that interfere with adjuvant HIPEC within 8 weeks (i.e.
             persisting intra-abdominal abscess, significant fascial dehiscence, enteric fistula)

          -  no intention to start routine adjuvant systemic therapy

          -  liver and/or lung metastases

          -  pregnant or lactating women

          -  unstable or uncompensated respiratory or cardiac disease

          -  serious active infections

          -  other concurrent chemotherapy

          -  hypersensitivity to fluorouracil, folinic acid or another substance of leucovorin or
             oxaliplatin

          -  stomatitis, ulceration in the mouth or gastrointestinal tract.

          -  severe diarrhea

          -  severe hepatic and / or renal dysfunction.

          -  plasma bilirubin concentrations greater than 85 μmol/l.

          -  pernicious anemia or other anaemias due to vitamin B12 deficiency.

          -  peripheral sensory neuropathy with functional impairment.
Clinical trial NCT02231164 (phase 3, status: terminated)
Conditions: carcinoma, non-small-cell lung
ICD codes: D02.20, D02.21, D02.22
Drugs: docetaxel, docetaxel, placebo, nintedanib
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, COC(=O)C1=CC=C2C(NC(=O)\C2=C(/NC2=CC=C(C=C2)N(C)C(=O)CN2CCN(C)CC2)C2=CC=CC=C2)=C1
Eligibility criteria:

        Inclusion criteria:

          -  Male or female patients of at least 18 years of age

          -  Histologically confirmed, adenocarcinoma of the lung, after failure of first line
             platinum-based chemotherapy.

        Exclusion criteria:

          -  More than one prior line of chemotherapy (i.e., 2nd or 3rd line chemotherapy) for
             advanced and/or metastatic (stage III B or IV NSCLC) or recurrent disease.

          -  Patients known to be positive for activating Epidermal Growth Factor Receptor (EGFR)
             mutation or anaplastic lymphoma kinase (ALK) translocation

          -  Previous therapy with other vascular endothelial growth factor (VEGF) or VEGFR
             inhibitors (other than bevacizumab) or docetaxel for the treatment of NSCLC at any
             time

          -  Prior monotherapy with an EGFR inhibitor except as maintenance therapy
Clinical trial NCT02234843 (phase 3, status: completed)
Conditions: venous thromboembolism
ICD codes: O88.22, O88.23, O88.211, O88.212, O88.213, O88.219
Drugs: rivaroxaban (xarelto, bay59-7939), rivaroxaban (xarelto, bay59-7939), standard of care
SMILES: ClC1=CC=C(S1)C(=O)NC[C@H]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O, ClC1=CC=C(S1)C(=O)NC[C@H]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O, OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Children aged birth to < 18 years with confirmed venous thromboembolism who receive
             initial treatment with therapeutic dosages of UFH (unfractionated heparin), LMWH (low
             molecular weight heparin) or fondaparinux and require anticoagulant therapy for at
             least 90 days. However, children aged birth to < 2 years with catheter-related
             thrombosis require anticoagulant therapy for at least 30 days.

          -  For children younger than 6 months:

               -  Gestational age at birth of at least 37 weeks.

               -  Oral feeding/nasogastric/gastric feeding for at least 10 days.

               -  Body weight ≥2600 g

        Exclusion Criteria:

          -  Active bleeding or bleeding risk contraindicating anticoagulant therapy

          -  An estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m*2 (in children
             younger than 1 year, serum creatinine results above 97.5th percentile excludes
             participation)

          -  Hepatic disease which is associated with either: coagulopathy leading to a clinically
             relevant bleeding risk, or ALT> 5x upper level of normal (ULN) or total bilirubin > 2x
             ULN with direct bilirubin > 20% of the total

          -  Platelet count < 50 x 109/L

          -  Sustained uncontrolled hypertension defined as > 95th age percentile

          -  Life expectancy < 3 months

          -  Concomitant use of strong inhibitors of both cytochrome P450 isoenzyme 3A4 (CYP3A4)
             and P-glycoprotein (P-gp), including but not limited to all human immunodeficiency
             virus protease inhibitors and the following azole antimycotics agents: ketoconazole,
             itraconazole, voriconazole, posaconazole, if used systemically

          -  Concomitant use of strong inducers of CYP3A4, including but not limited to rifampicin,
             rifabutin, phenobarbital, phenytoin and carbamazepine

          -  Childbearing potential without proper contraceptive measures, pregnancy or breast
             feeding
Clinical trial NCT02240108 (phase 3, status: terminated)
Conditions: crohn's disease
ICD codes: K50.90, K50.913, K50.914, K50.911, K50.912, K50.918, K50.919
Drugs: rifaximin eir, placebo
SMILES: [H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    the study was terminated early due to difficulty in enrollment and lack of clinical study drug
    access.
  
Eligibility criteria:

        Major Inclusion Criteria:

          -  Moderate, non-fistulizing Crohn's disease in the ileum and/or colon prior to
             randomization; and a SES-CD score of ≥7 (confirmed by centralized endoscopy reading).

          -  During the screening period, the participant will need to have certain average daily
             scores for abdominal pain and average number of liquid/very soft stools.

        Major Exclusion Criteria:

          -  Pregnant or lactating females. Females of childbearing (reproductive) potential must
             have a negative serum pregnancy test at screening and agree to use a highly effective
             method(s) of contraception throughout their participation in the study. Diagnosis of
             ulcerative or indeterminate colitis.

          -  Diagnosis of Celiac Disease.

          -  Bowel surgery within 12 weeks prior to screening and/or has surgery planned or deemed
             likely for Crohn's disease during the study period.

          -  Presence of an ileostomy or colostomy.

          -  Known fixed symptomatic stenosis/stricture of the small or large bowel.

          -  Had more than one segmental colonic resection.

          -  Had more than 3 small bowel resections or symptoms associated with short bowel
             syndrome.

          -  Current evidence of peritonitis.

          -  History or evidence of colonic mucosal dysplasia.

          -  History or evidence of adenomatous colonic polyps that have not been removed.

          -  Unwilling to be tapered off corticosteroids by Week 8 or the participant is known by
             the Investigator to be steroid-dependent.

          -  Has used a biologic within 12 weeks of randomization.

          -  Used cyclosporine, tacrolimus, sirolimus, mycophenolate mofetil, or similar drugs
             within 8 weeks prior to randomization.

          -  Had rectal administration of 5-aminosalicylic acid (5-ASA) or corticosteroid
             enemas/foams/ suppositories within 2 weeks prior to screening visit.
Clinical trial NCT02240121 (phase 3, status: terminated)
Conditions: crohn's disease
ICD codes: K50.90, K50.913, K50.914, K50.911, K50.912, K50.918, K50.919
Drugs: rifaximin eir, placebo
SMILES: [H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    the study was terminated early due to difficulty in enrollment and lack of clinical study drug
    access.
  
Eligibility criteria:

        Major Inclusion Criteria:

          -  Moderate, non-fistulizing Crohn's disease in the ileum and/or colon prior to
             randomization; and a SES-CD score of ≥7 (confirmed by centralized endoscopy reading).

          -  During the screening period, the participant will need to have certain average daily
             scores for abdominal pain and average number of liquid/very soft stools.

        Major Exclusion Criteria:

          -  Pregnant or lactating females. Females of childbearing (reproductive) potential must
             have a negative serum pregnancy test at screening and agree to use a highly effective
             method(s) of contraception throughout their participation in the study. Diagnosis of
             ulcerative or indeterminate colitis.

          -  Diagnosis of Celiac Disease.

          -  Bowel surgery within 12 weeks prior to screening and/or has surgery planned or deemed
             likely for Crohn's disease during the study period.

          -  Presence of an ileostomy or colostomy.

          -  Known fixed symptomatic stenosis/stricture of the small or large bowel.

          -  Had more than one segmental colonic resection.

          -  Had more than 3 small bowel resections or symptoms associated with short bowel
             syndrome.

          -  Current evidence of peritonitis.

          -  History or evidence of colonic mucosal dysplasia.

          -  History or evidence of adenomatous colonic polyps that have not been removed.

          -  Unwilling to be tapered off corticosteroids by Week 8 or the participant is known by
             the Investigator to be steroid-dependent.

          -  Has used a biologic within 12 weeks of randomization.

          -  Used cyclosporine, tacrolimus, sirolimus, mycophenolate mofetil, or similar drugs
             within 8 weeks prior to randomization.

          -  Had rectal administration of 5-aminosalicylic acid (5-ASA) or corticosteroid
             enemas/foams/ suppositories within 2 weeks prior to screening visit.